Join
Live feed
·
PRReleasevia Quantisnow
NLS Pharmaceutics Ltd. logo

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

ByQuantisnow·Wall Street's wire, on your screen.
NLSP· NLS Pharmaceutics Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NLSP (NLS Pharmaceutics Ltd.) and more on Quantisnow.